Get started
Author

Birgitte Mayland Havelund

Observed names: B. Havelund, B. Mayland Havelund, B.M Havelund, B.M. Havelund, BIRGITTE MAYLAND HAVELUND, Birgitte Havelund, Birgitte M. Havelund, Havelund, Birgitte, Havelund, Birgitte M., Havelund, Birgitte Mayland
Observed institutions: University of Southern Denmark, Odense University Hospital, University of Chieti-Pescara, Vejle Sygehus, Region of Southern Denmark, Lillebaelt Hospital
ORCID: 0000-0002-6566-5367
Observed ORCID: 0000-0002-6566-5367
OpenAlex ID: A5014020558
Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
2023 · Lars Henrik Jensen, Silvia Regina Rogatto, et al. · Journal of Experimental & Clinical Cancer Research · 76
PDF
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma
2013 · Karen-Lise G. Spindler, Morten M. Sorensen, et al. · Acta Oncologica · 60
PDF
Long-Term Results of a Randomized Trial in Locally Advanced Rectal Cancer: No Benefit From Adding a Brachytherapy Boost
2014 · Ane L. Appelt, Ivan R. Vogelius, et al. · International Journal of Radiation Oncology*Biology*Physics · 57
Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer
2012 · Birgitte M. Havelund, Paw C. Holdgaard, et al. · Nuclear Medicine Communications · 43
Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer
2020 · Luisa Matos do Canto, Mateus Camargo Barros-Filho, et al. · Cancers · 28
PDF
NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
2019 · Lars Henrik Jensen, René Olesen, et al. · Cancers · 27
PDF
Curative chemoradiation for low rectal cancer: Primary clinical outcomes from a multicenter phase II trial.
2022 · Lars Henrik Jensen, Signe Risum, et al. · Journal of Clinical Oncology · 24
NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
2022 · Louise Raunkilde, Torben Frøstrup Hansen, et al. · Cancers · 20
PDF
Nordic anal cancer (NOAC) group consensus guidelines for risk-adapted delineation of the elective clinical target volume in anal cancer
2023 · Martin P. Nilsson, Christine Undseth, et al. · Acta Oncologica · 19
PDF
Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response
2019 · Luisa Matos do Canto, Sarah Santiloni Cury, et al. · Scientific Reports · 18
PDF
Pretreatment HIF-1α and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer.
2011 · Birgitte Mayland Havelund, Flemming Brandt Sørensen, et al. · PubMed · 17
Immunohistological expression of HIF ‐1α, GLUT ‐1, B cl‐2 and K i‐67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer
2012 · Birgitte Mayland Havelund, Flemming Brandt Sørensen, et al. · Apmis · 12
Recommendations for radiotherapy quality assurance in clinical trials
2025 · Camilla Panduro Nielsen, Eva Samsøe, et al. · Radiotherapy and Oncology · 10
PDF
Treatment planning for patients with low rectal cancer in a multicenter prospective organ preservation study
2024 · Dennis Tideman Arp, Ane L. Appelt, et al. · Physica Medica · 10
PDF
The Influence of Tissue Ischemia on Biomarker Expression in Colorectal Cancer
2012 · Birgitte M. Havelund, Dorte A. Olsen, et al. · Applied immunohistochemistry & molecular morphology · 10
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
2023 · Louise Raunkilde, Torben Frøstrup Hansen, et al. · Acta Oncologica · 8
Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial
2025 · Johanne D. Lyhne, Vibeke B. Hansen, et al. · Cardio-Oncology · 6
PDF
Risk factors and outcome following salvage surgery for squamous cell carcinoma of the anus
2023 · Julie Borg, Karen-Lise Garm Spindler, et al. · European Journal of Surgical Oncology · 6
PDF
Re‐exposure to immunotherapy in metastatic colon cancer: A case report
2021 · Tonje Riise Hamre, Julie Kristine Stougaard, et al. · Clinical Case Reports · 6
PDF
Single nucleotide polymorphisms in the HIF-1α gene and chemoradiotherapy of locally advanced rectal cancer
2012 · BIRGITTE MAYLAND HAVELUND, KAREN-LISE GARM SPINDLER, et al. · Oncology Letters · 6
PDF
Intensified Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Anus—A Population-Based Experience from the Danish Anal Cancer Group
2021 · Karen Lycke Wind, Lisbeth Riber, et al. · Cancers · 5
PDF
Feasibility of weekly cisplatin and radiotherapy for localized anal cancer – A Danish anal cancer group report
2024 · Anne Vittrup Jakobsen, Camilla Jensenius Skovhus Kronborg, et al. · Radiotherapy and Oncology · 4
400MO Curative chemoradiation for low rectal cancer: Early clinical outcomes from a multicentre phase II trial
2020 · L.H. Jensen, L.Ø. Poulsen, et al. · Annals of Oncology · 4
Acute toxicity and quality of life in dose-escalated proton reirradiation for locally recurrent rectal cancer: The prospective ReRad II trial
2025 · C.G Truelsen, H.S Rønde, et al. · Clinical and Translational Radiation Oncology · 3
PDF
Inter-fraction motion robustness in a prospective phase II trial on dose-escalated proton reirradiation for locally recurrent rectal cancer
2024 · Christina G. Truelsen, Heidi S. Rønde, et al. · Physics and Imaging in Radiation Oncology · 3
PDF
Works count: 69
Citation count: 496
H-index: 12
I10-index: 15
Year
Topic
Type